All In Biotech

Drug Trial Radar · NCT05910801

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): a Phase II Study with Safety Lead-In

Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 4, 2024

Primary completion

Dec 30, 2029

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Academic and Community Cancer Research UnitedAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab, lenalidomide and venetoclax together may kill cancer cells more efficiently in patients with relapsed or refractory mantle cell lymphoma.

Conditions

  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma

Interventions

  • BiopsyProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Computed TomographyProcedure

    Undergo CT scan

  • LenalidomideDrug

    Given PO

  • Lumbar PunctureProcedure

    Undergo lumbar puncture

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Positron Emission TomographyProcedure

    Undergo PET/CT scan

  • TafasitamabBiological

    Given IV

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: Up to 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

  • M D Anderson Cancer Center

    Houston, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.